Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Inclusion Criteria: * 1\. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form. * 2\. Age ≥ 18 years. * 3\. Histopathology confirmed Non-small cell lung cancer. * 4\. confirmed or probable leptomeningeal metastases according to EANO-ESMO guidelines or known leptomeningeal metastases progression after third generation of EGFR-TKIs failure. * 5.Leptomeningeal metastasis (LM) is defined by the presence of typical clinical symptoms, positive cerebrospinal fluid (CSF) cytology, detection of cell-free DNA (cfDNA) in CSF by next-generation sequencing (NGS), or imaging findings consistent with typical meningeal metastases. * 6.ECOG 0 - 2. * 7\. Predicted survival ≥ 12 weeks. * 8\. Adequate bone marrow hematopoiesis and organ function. Exclusion Criteria: * 1\. Previously received intrathecal pemetrexed therapy for locally advanced or metastatic disease. * 2\. Subjects who have received any of the following treatments must be excluded: Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity. Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose. * 3\. Presence of spinal cord compression. * 4\. History of other malignant tumors within 2 years. * 5\. Adverse events (except alopecia of any degree) of CTCAE \> grade 4 due to prior treatment (e.g., adjuvant chemo…